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Abstract
Background: Many mutations in the α-tectorin gene (TECTA) have been reported to cause non-syndromic hearing
loss (NSHL) in either a dominant or recessive inheritance pattern. Among the identified TECTA mutations, H1400Y
has been associated with NSHL in two independent studies. However, its exact role in contributing to genetic
hearing loss remains elusive.
Case presentation: We herein report the whole-exome sequencing of a proband presenting with prelingual, non-
progressive, mild-to-moderate hearing loss in a simplex family. By using trio-based whole-exome sequencing, we
found two heterozygous mutations of R1890C and H1400Y in the ZP and ZA domains of TECTA, respectively.
R1890C, previously reported as a pathogenic autosomal dominant mutation of genetic hearing loss, was found to
be inherited in a de novo pattern, causing hearing loss in the proband. By contrast, H1400Y was not segregated in
this family, and one family member with normal hearing also carried the H1400Y mutation.
Conclusion: According to the hearing loss-specific American College of Medical Genetics and Genomics (ACMG)
guidelines, we conclude that H1400Y should be disqualified as a cause of genetic hearing loss. True pathogenic
variants causing genetic hearing loss should be more deliberately reported in accordance with ACMG guidelines.
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Background
The tectorial membrane is an extracellular matrix over-
lying the organ of Corti. By making contact with the
stereocillia of specialized sensory hair cells, the tectorial
membrane plays an important role in inducing the
movement of these hair cells via intracochlear sound
transmission [1]. The TECTA gene encodes α-tectorin, a
protein of 2156 amino acid residues, that is a major
component of the non-collagenous glycoproteins com-
prising the tectorial membrane [2]. TECTA is known as
a causative gene of both autosomal dominant (DFNA8/
A12) and autosomal recessive (DFNB21) non-syndromic
sensorineural hearing loss (NSHL) [3, 4]. α-Tectorin is
composed of several functional domains, including the
entactin domain, four von Willebrand factor-like type D
domains in the zonadhesin (ZA) domain, and the
C-terminal zona pellucida (ZP) domain [5]. Autosomal
dominant mutations in TECTA result in a broad
spectrum of hearing loss depending on the domain in
which the mutation occurs [5, 6], whereas the recessive
mutations in TECTA cause mid-frequency hearing loss
with a cookie-bite or U-shape audiometric configuration
[7, 8]. Analysis of genotype–phenotype correlations indi-
cate that missense mutations in the ZP domain primarily
affect mid-frequency hearing loss while mutations in the
ZA domain affect high-frequency hearing loss [9]. Despite
several reports indicating an association of TECTA muta-
tions with hereditary hearing loss, the precise molecular
mechanism remains unclear. Furthermore, considering
that TECTA mutations account for 4% of all cases of
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autosomal dominant NSHL (ADNSHL), TECTA-related
ADNSHL should be regarded as one of the most frequent
subtypes of ADNSHL [9].
Here, we report a 4-year-old Korean girl with
non-progressive, prelingual, mid-frequency, and
mild-to-moderate hearing loss, who had two missense
mutations in the ZP and ZA domains of TECTA. Based
on familial segregation analyses, we concluded that
R1890C is a causative mutation for hereditary hearing
loss, whereas H1400Y is not.
Case presentation
With approval from the Institutional Review Board of
the Severance Hospital, Yonsei University Health Sys-
tem (Seoul, Republic of Korea), a three-generation pedi-
gree was obtained from the family by genetic counseling.
The family comprised 11 individuals, four of whom par-
ticipated in the study. The four members from three
generations of the family were evaluated at Yonsei Uni-
versity Severance Hospital. For phenotype evaluation, we
reviewed the medical and developmental history, and
conducted physical examinations, pure tone audiometry,
and a speech evaluation.
The proband (III-1) was a 4-year-old female of family
YUHL-165 who failed to pass the neonate hearing
screening at birth and was thus referred to our depart-
ment for diagnostic auditory brain stem response (ABR)
testing. There was no family history related to hearing
loss (Fig. 1a). She had no other risk factor of hearing loss
and her ABR threshold was determined to be 45 dB nHL
on the right and 40 dB nHL on the left. According to the
national guideline of neonate hearing loss, we decided to
perform the ABR again 3 months later and found no sig-
nificant change in the ABR threshold (Fig. 1b). The tem-
poral bone computed tomogram showed no inner ear
anomaly (Fig. 1c). Audiogram performed at 4 years of
follow-up revealed a mild to moderate flat shape in both
ears and did not show any progression of hearing loss
compared with the previously determined ABR thresh-
old. She also did not respond in the DPOAE test, which
indicates prelingual, non-progressive, mild-to-moderate
sensorineural hearing loss bilaterally. All other family
members had normal hearing (Fig. 1d).
To identify the genetic cause of hearing loss in this
family, next-generation sequencing (NGS) was per-
formed. Among the 2368 variants in 182 known hearing
loss genes detected in our pipeline, 11 were manually
reviewed for pathogenicity determination since their al-
lele frequencies in the population database were under
0.01 (1%). Among these 11 variants in 10 hearing loss
genes, two heterozygous missense variants in the TECTA
gene were identified. We analyzed Sanger sequencing re-
sults and NGS alignment results of the R1890C variant
and its adjacent synonymous variant. As the c.5634C > T
synonymous variant was inherited from the mother and
therefore located on the maternal allele, the cis/trans
Fig. 1 a Pedigree of the family with a de novo mutation causing hearing loss in the proband (filled circle). b Auditory brainstem response (ABR)
of the proband (III-1) at 1 month after birth. c Temporal bone computed tomogram of the inner ear (III-1) d Pure-tone audiogram of the father
(II-1), mother (II-2), and proband (III-1). Red and blue indicate thresholds for the right and left ears, respectively. Solid and dashed lines refer to
air- and bone-conduction, respectively
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status of the c.5634C > T variant and de novo R1890C
variant was revealed by NGS fragment alignment with the
Integrative Genomics Viewer (IGV). Since the two vari-
ants were in trans, the de novo R1890C variant was con-
firmed to be located on the paternal allele. Therefore,
both the H1400Y and R1890C variants were located on
the paternal allele, suggesting a cis status of the two vari-
ants (Fig. 2).
The minor allele frequencies of each variant were deter-
mined in presumptively normal hearing population data-
bases, including ESP6500, 1000 Genomes Project, and the
Korean database (National Biobank of Korea, NBK)
(Table 1). The variant R1890C was absent from control in-
dividuals, which translates into a status of “PM2” (i.e., ab-
sent in population databases) according to the American
College of Medical Genetics and Genomics (ACMG)
guideline. However, the other variant, H1400Y, is present
at a relatively low allele frequency in controls and can be
translated into “BS2” (i.e., observation in controls incon-
sistent with disease penetrance) because the hearing of the
father with H1400Y was normal. From the perspective of
in silico predictions, both variants were equally qualified
to receive the status “PP3” (i.e., multiple computational
evidences), with five out of the eight algorithms suggesting
a deleterious effect (Tables 1 and 2). An extensive litera-
ture review with a search of the Human Gene Mutation
Database (HGMD), Deafness Variation Database, ClinVar,
and PubMed databases showed that each variant has been
described in two reports; thus, both variants qualified for
category “PP5” (i.e., recent reputable source without func-
tional evidence). Considering all of these lines of evidence
together, the two missense variants were suspected to ad-
ditively contribute to the phenotype of hearing loss with
an autosomal recessive mode of inheritance (DFNB21).
Among the two candidate variants in the TECTA
gene, H1400Y was revealed to be inherited from the
proband’s father in the trio study (Fig. 2). However,
R1890C was not observed in either parent, indicating
de novo status. Although this result allowed us to as-
sign the status “PS2” (i.e., de novo, paternity and ma-
ternity confirmed) to the R1890C variant (Table 2), it
also indicated the requirement of further phenotypic
analysis of the parents since two scenarios were pos-
sible: 1) R1890C and H1400Y could act as two addi-
tive variants in an autosomal recessive inheritance
pattern, or 2) R1890C could independently act as a
single mutation in an autosomal dominant inheritance
pattern. According to previous reports, dominant
TECTA mutations are generally associated with stable
and post-lingual progressive hearing loss, whereas re-
cessive TECTA mutations are generally associated
with pre-lingual stable hearing loss. Therefore,
phenotype-based genotype interpretation was further
applied for identification of true variants.
According to the original ACMG guideline interpret-
ation, the variants R1890C and H1400Y could be classi-
fied as “likely pathogenic” and “variant of uncertain
significance”, respectively (Table 2). These results could
not determine whether the TECTA mutation is inherited
in an autosomal dominant or recessive mode. However,
application of the updated hearing loss-specified ACMG
guideline maximized the evidential weight for each com-
ponent, thereby allowing us to designate R1890C as
“pathogenic” rather than “likely pathogenic”, and
H1400Y as “benign” rather than “variant of uncertain
significance” (Table 2).
Discussion and conclusion
ADNSHL has both genetically and clinically heteroge-
neous characteristics, and 24 associated genes have been
identified to date [10]. TECTA is one of the most com-
mon genes responsible for ADNSHL and has been asso-
ciated with various types of hearing loss in terms of
progression and affected frequency range [3, 4]. The
position of the mutations in either the ZP or ZA domain
of the encoded α-tectorin protein, and the spectrum of
the amino acid substitutions determine the pathogenic
characteristics of the TECTA mutation. Currently estab-
lished genotype-phenotype correlations in TECTA indi-
cate that mutations in the ZP and ZA domains are
generally related to mid- and high-frequency hearing
loss, respectively [4–6, 11]. However, in 2011, Hildeb-
rand et al. [9] challenged these genotype-phenotype cor-
relations based on the results of a large cohort study
indicating that ZA domain mutations are also associated
with mid-frequency hearing loss. It is possible that if
mutations of both domains similarly affect processing of
α-tectorin, the ZA mutation might disrupt polypeptide
assembly, thereby having a distinct impact on frequency
ranges [12].
Two TECTA missense mutations, R1890C and
H1400Y, were detected in the proband of the present
trio study. The variant H1400Y is located in exon 12
corresponding to the ZA domain of α-tectorin, whereas
R1890C is located in the ZP domain. R1890C was previ-
ously reported as a pathogenic mutation with a high
level of evidence [11]. However, H1400Y was not clearly
proven to be pathogenic in two previous studies [13, 14].
One study involved a Japanese family with heterozygous
H1400Y and T1866M mutations of TECTA. Four of the
five affected family members were evaluated, all of
whom demonstrated bilateral, mild to moderate sym-
metric sensorineural hearing loss, affecting the mid fre-
quencies. Interestingly, the H1400Y mutation was
present in the cis-form with the other deleterious muta-
tion T1866M. The authors suggested that T1866M was
likely the causative mutation of the hearing impairment
in this family, although the effect of H1400Y could not
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be completely ruled out at that time [14]. In another re-
port, H1400Y was identified in a patient with congenital
severe hearing loss, but no familial segregation study
was performed [13]. In 2006, Plantinga et al. [11] first re-
ported the R1890C mutation, which was combined with
the T83M mutation in α-tectorin, in a Dutch family with
autosomal dominant mid-frequency hearing loss.
R1890C is located in the ZP domain of α-tectorin,
whereas T83M could not be aligned to a specific do-
main. Considering the phenotype, position of the muta-
tion, and molecular mechanism of cysteine mutation,
the authors suggested that the impact of the T83M mu-
tation is negligible, whereas R1890C is likely to be causa-
tive for genetic hearing loss. Based on the incongruent
genotype-phenotype results of these two studies, we as-
sumed that H1400Y is unlikely to be pathogenic. Sup-
porting this assumption, the proband of the present
study had two missense mutations and the audiogram
showed mild-to-moderate hearing loss, while her father
with only the H1400Y mutation showed a completely
normal audiogram. Furthermore, the other variant
R1890C was revealed to be a de novo mutation based on
the familial segregation study, suggesting a high likeli-
hood of pathogenicity.
Interestingly, all of the mutations of TECTA associated
with ADNSHL identified to date are missense variants,
while nonsense mutations are associated with an auto-
somal recessive pattern of inheritance. As mentioned
above, the specific pattern of hearing loss caused by a
TECTA mutation depends on the affected domains.
Missense mutations in the ZP and ZA domains are gen-
erally related to mid- and high-frequency hearing loss,
respectively. However, the proband in this study showed
a flat-type audiogram, which seems to affect the high
frequency. There are several possibilities to explain this
finding. First, the reliability of the proband’s pure tone
audiometry could be relatively poor due to her young
age. Second, the synergistic effect of the two mutations
cannot be completely excluded. Third, the post-lingual
hearing loss may be due to a genetic cause inherited
from her father. Therefore, accurate follow-up hearing
testing will be needed for this family.
Unfortunately, there has been no in vitro functional
assay to evaluate the mechanism by which TECTA muta-
tions affect hearing loss. In this case, other available lines
of evidence such as those derived from segregation stud-
ies should be incorporated to pinpoint true genetic
causes. The combination of genetic and segregation ana-
lyses can help to provide several counseling strategies
for determining the progression, prediction, and thera-
peutic application for this young patient.
Recent improvements of variant interpretation guide-
lines, including the hearing loss-specified ACMG guide-
line established by the ClinGen Working Group,
advocated our findings. Compared to the original
ACMG guideline, which provided inconclusive results
even when conducting a familial segregation study, the
optimized ACMG guideline maximized the pathogen-
icity evaluation results and pinpointed the true patho-
genic mutation. As TECTA is one of the major
Fig. 2 Electropherograms for the family YUHL-165 showing the heterozygous R1890C and H1400Y mutations of TECTA in the proband and only
the H1400Y mutation in the father. a Segregation of the TECTA gene showing the H1400Y substitution. b Segregation of the TECTA gene showing
the R1890C substitution. c Use of synonymous variant in the TECTA gene for cis/trans status determination of the two missense variants
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contributing causative genes of hearing loss, accurate ap-
plication of hearing loss-specified ACMG rules is ex-
pected to enhance classification of all of the variants
identified to date.
In conclusion, we identified the R1890C mutation in
the TECTA gene as a genetic cause of hearing loss,
whereas the H1400Y variant was determined to be an in-
nocent bystander. To the best of our knowledge, this is
the first study to provide clear evidence as to whether or
not H1400Y is responsible for hearing loss, including re-
sults from a familial segregation study and hearing
loss-specified ACMG guideline application. Therefore,
this study is expected to contribute to gaining a better
understanding of the TECTA gene mutation spectrum.
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